Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tailored antibiotic regimen shorten endocarditis treatment without risk?

NCT ID NCT05144399

Disease control Sponsor: Herlev Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial investigates whether a shorter course of antibiotics, tailored to each patient's response, can treat left-sided endocarditis as safely as the standard 4-6 week regimen. Adults with endocarditis caused by specific bacteria (Streptococci, Enterococcus faecalis, or Staphylococcus aureus) receive an accelerated treatment plan based on their individual clinical data. The goal is to reduce hospital stays and associated risks while maintaining effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
accelerated antibiotic treatment tailored to individual response
What this could lead to
If successful, this could shorten hospital stays and reduce risks like mental strain and loss of function for patients with endocarditis, while saving healthcare costs.
What could go wrong
This is an early-stage trial testing a non-inferiority approach, so the shorter treatment might prove less effective or safe than standard care. Results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

508 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Apr 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients hospitalized and diagnosed with bacterial, left-sided endocarditis as determined by the department clinician responsible based on the revised Duke criteria. 2. The patient may be included \<14 days after beginning of relevant antibiotic treatment. 3. Left-sided endocarditis with one of the following microorganisms: Streptococci; Enterococcus faecalis; Staphylococcus aureus. 4. Patients ≥ 18 years. Exclusion Criteria: 1. Known / suspected immunocompetence (HIV, chemotherapy, prednisolone treatment (\> 20 mg / day)). 2. Incapability to give informed consent for participation. 3. Relapse Endocarditis (Endocarditis with the same bacteria within six months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial endocarditis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial endocarditis endocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endocarditis

Contacts and locations

Locations

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Brigham and Womens Hospital

    Boston, Massachusetts, 02115, United States

  • Gødstrup Regional Hospital

    Gødstrup, Denmark

  • Herlev Hospital

    Herlev, 2730, Denmark

  • Hillerød Hospital

    Hillerød, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Odense sygehus

    Odense, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Roskilde Sygehus, Zealand University hospital

    Roskilde, Denmark

  • Skejby Sygehus

    Aarhus, Denmark

  • Skåne University Hospital

    Lund, Sweden

  • Vejle Hospital

    Vejle, Denmark

  • Viborg Hospital

    Viborg, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.